| Income Statement | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Total revenue | 7,406,000 | - | ||
| Cost of goods sold | 2,316,000 | - | ||
| Selling, general and administrative | 19,628,000 | - | ||
| Research and development | 145,000 | 514,814 | ||
| Professional fees | - | 1,605,525 | ||
| General and administrative expenses | - | 1,110,084 | ||
| Amortization of intangible assets | 679,000 | - | ||
| Total operating expenses | 22,768,000 | 3,230,423 | ||
| Operating loss | -15,362,000 | -3,230,423 | ||
| Interest expense | 1,346,000 | - | ||
| Interest income and other income | 5,000 | 0 | ||
| Interest expense | - | 218,516 | ||
| Total other (expense) income | -1,341,000 | -218,516 | ||
| Net loss before provision for income taxes | -16,703,000 | -3,448,939 | ||
| Provision for income taxes | -465,000 | 0 | ||
| Net loss | - | -3,448,939 | ||
| Net loss and comprehensive loss | -16,238,000 | - | ||
| Net loss per common share - basic | -5.3 | -5.38 | ||
| Net loss per common share - diluted | -5.3 | -5.38 | ||
| Weighted average number of common shares outstanding during the period - basic | 3,061,488 | 640,518 | ||
| Weighted average number of common shares outstanding during the period - diluted | 3,061,488 | 640,518 | ||
Pelthos Therapeutics Inc. (PTHS)
Pelthos Therapeutics Inc. (PTHS)